The use of International Reference Pricing (IRP) as a cost-containment tool is widely implemented across countries with varying degrees of rule complexity. Despite IRP being argued to cause multiple challenges such as timely patient access, affordability challenges, and a potential impact on pharmaceutical industry sustainability and R&D expenditure.

This comprehensive whitepaper developed by Pricia explores how IRP affects patient access and affordability, IRP's impact on pharmaceutical sustainability and R&D, best practices for managing international prices under IRP, and features real-world case studies. 

Download this whitepaper to gain an in-depth understanding of IRP and its impact on pharmaceutical pricing strategies.